SC
CRSP icon

Scholtz & Company’s CRISPR Therapeutics CRSP Stock Holding History

Scholtz & Company’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,980
Closed -$222K – 64
2021
Q3 		$222K Sell
1,980
-805
-29% -$101K 0.08% 64
2021
Q2 		$451K Sell
2,785
-67
-2% -$8.15K 0.15% 58
2021
Q1 		$348K Sell
2,852
-77
-3% -$11.6K 0.13% 59
2020
Q4 		$448K Buy
2,929
+364
+14% +$43K 0.18% 58
2020
Q3 		$215K Buy
+2,565
New +$228K 0.09% 65

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Scholtz & Company's CRSP Position: Q4 2021 in Review

Scholtz & Company sold out of CRISPR Therapeutics (CRSP) in Q4 2021, closing a stake of 1,980 shares — an estimated $222K sold.

Scholtz & Company first reported a position in CRSP in Q3 2020 and held it in 5 quarters. The position peaked at $451K in Q2 2021. 446 funds tracked by Wall St. Rank hold CRSP as of Q4 2021.

  • Scholtz & Company reported no remaining CRISPR Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Scholtz & Company sold 1,980 CRISPR Therapeutics shares in Q4 2021, an estimated $222K.
  • Scholtz & Company first reported a position in CRISPR Therapeutics in Q3 2020 and held it in 5 quarters.
  • Scholtz & Company's CRISPR Therapeutics position peaked at $451K in Q2 2021.
  • 446 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2021.

Based on Scholtz & Company's 13F filing for Q4 2021, filed 15 Feb 2022.